Company Filing History:
Years Active: 2022
Title: Catarina Leitâo: Innovator in Cancer Immunotherapy
Introduction
Catarina Leitâo is a prominent inventor based in Lisbon, Portugal. She has made significant contributions to the field of cancer immunotherapy, particularly through her innovative research and patent developments. Her work focuses on high avidity antigen recognizing constructs, which have the potential to revolutionize cancer treatment.
Latest Patents
Catarina Leitâo holds a patent for "High avidity antigen recognizing constructs." This invention pertains to novel constructs, such as antibodies or T cell receptors, that specifically bind to the melanoma-associated antigen (MAGE) A1. The constructs are particularly useful for the diagnosis, prevention, or therapy of tumorous diseases characterized by the specific expression of the MAGE-A1 antigen. Additionally, her invention includes nucleic acids, vectors, and host cells, such as CD4 or CD8 positive T cells, which encode, comprise, or present the antigen recognizing constructs. This innovation provides new approaches for immune therapy, specifically adoptive T cell therapy, for treating cancer.
Career Highlights
Catarina Leitâo is affiliated with the Max Delbrück Center for Molecular Medicine in Berlin-Buch. Her work at this esteemed institution has allowed her to collaborate with leading scientists and contribute to groundbreaking research in the field of molecular medicine.
Collaborations
Catarina has worked alongside notable colleagues, including Thomas Blankenstein and Matthias Obenaus. Their collaborative efforts have further advanced the understanding and application of cancer immunotherapy.
Conclusion
Catarina Leitâo's innovative work in developing high avidity antigen recognizing constructs marks her as a key figure in the fight against cancer. Her contributions to immunotherapy are paving the way for new treatment options and improving patient outcomes.